Elite Pharmaceuticals Inc (ELTP)

[WeeZuhl]

The Michael J. Fox Foundation (MJFF) funded pre-clinical work to make that connection, as well as the Phase II trial. In 2014, isradipine researchers received a $23 million grant from the National Institutes of Health to move the Safety, Tolerability and Efficacy Assessment of Dynacirc® for PD (STEADY-PD) study into Phase III efficacy testing.

$23 million from NIH just to fund the isradipine Phase 3. Millions more from NIH and MJFF for pre-clinicals and Phase 2. Massive public spending on behalf of PD patients and to the benefit of Elite shareholders. Close to half the market cap of the company spent but not a dime from ELTP treasury. Amazing.